Cigna Group（CI）株式概要
シグナ・グループはその子会社とともに、米国で保険および関連商品・サービスを提供している。 詳細
CI Community Fair Values
Create NarrativeSee what 94 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
The Cigna Group 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$281.45 |
| 52週高値 | US$315.47 |
| 52週安値 | US$239.51 |
| ベータ | 0.30 |
| 1ヶ月の変化 | 0.78% |
| 3ヶ月変化 | 0.55% |
| 1年変化 | -4.82% |
| 3年間の変化 | -4.19% |
| 5年間の変化 | 20.86% |
| IPOからの変化 | 7,189.35% |
最新ニュース
ナラティブ更新 • Jun 15
CI: PBM Transition Execution And Dividend Strength Will Support Future Share Upside
Analysts have slightly adjusted their price target for Cigna Group, with the fair value estimate moving from about $341.50 to roughly $340.92 as updated assumptions for discount rate, revenue growth, profit margins, and future P/E filter through their models. What's in the News Deutsche Bank and Barclays shifted their views on Cigna Group to more neutral stances, citing multi year uncertainty and risks tied to the pharmacy benefit manager transition, including questions around the insurance portfolio and PBM model.ナラティブ更新 • Jun 01
CI: Portfolio Reshaping And CEO Transition Will Support Future Share Upside
Analysts have nudged their price target for Cigna Group slightly higher to about $341.50, reflecting updated assumptions for revenue, profit margins and a modestly higher future P/E multiple. What's in the News Cigna reported Q1 2026 adjusted EPS of US$7.79 on revenue of US$68.5b, above analyst expectations, and raised full year adjusted EPS guidance to at least US$30.35 per share, according to recent earnings coverage.Recent updates
ナラティブ更新 • Jun 15
CI: PBM Transition Execution And Dividend Strength Will Support Future Share Upside
Analysts have slightly adjusted their price target for Cigna Group, with the fair value estimate moving from about $341.50 to roughly $340.92 as updated assumptions for discount rate, revenue growth, profit margins, and future P/E filter through their models. What's in the News Deutsche Bank and Barclays shifted their views on Cigna Group to more neutral stances, citing multi year uncertainty and risks tied to the pharmacy benefit manager transition, including questions around the insurance portfolio and PBM model.ナラティブ更新 • Jun 01
CI: Portfolio Reshaping And CEO Transition Will Support Future Share Upside
Analysts have nudged their price target for Cigna Group slightly higher to about $341.50, reflecting updated assumptions for revenue, profit margins and a modestly higher future P/E multiple. What's in the News Cigna reported Q1 2026 adjusted EPS of US$7.79 on revenue of US$68.5b, above analyst expectations, and raised full year adjusted EPS guidance to at least US$30.35 per share, according to recent earnings coverage.Seeking Alpha • May 18
Cigna: Shares Marching To Full Recovery
Summary Cigna Group is reiterated as a "Buy," driven by strong Q1 2026 results, raised guidance, and sustained business momentum. CI’s pharmacy and behavioral health segments are fueling revenue growth, while divestitures and PBM reform temporarily temper 2026 earnings. Shares trade at a 25% discount to a $377 fair value estimate, offering potential 15% annual total returns through 2031. Cigna’s robust balance sheet, market-leading dividend coverage, and growth catalysts in biosimilars and behavioral health underpin the investment thesis. Read the full article on Seeking Alpha分析記事 • May 04
The The Cigna Group (NYSE:CI) First-Quarter Results Are Out And Analysts Have Published New Forecasts
The Cigna Group ( NYSE:CI ) came out with its first-quarter results last week, and we wanted to see how the business is...ナラティブ更新 • May 02
CI: Leadership Transition And Buybacks Will Support Future Share Upside
Analysts have increased their price target on Cigna Group by about $1. This reflects small adjustments to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions in their models.ナラティブ更新 • Apr 17
CI: Leadership Transition And Buybacks Will Drive Future Upside
Analysts have trimmed their average price target on Cigna Group by about $0.38 to roughly $338.42, reflecting small updates to fair value estimates, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The Cigna Group plans a leadership transition, with current CEO David M.ナラティブ更新 • Apr 02
CI: Leadership Transition And Onsite Care Expansion Will Drive Future Upside
Analysts have slightly refined their view on Cigna Group, trimming the price target by a fraction to $338.79 as updated assumptions for revenue growth, profit margins, and future P/E bring the model into closer alignment with their latest expectations. What's in the News Cigna Group plans a leadership transition, with David M.ナラティブ更新 • Mar 19
CI: Onsite Care Expansion And Leadership Transition Will Support Future Upside
Analysts have nudged their fair value estimate for Cigna Group from about $336.67 to roughly $338.80. This reflects updated views on revenue growth, profit margins, and an anticipated forward P/E of around 13.43x.ナラティブ更新 • Mar 05
CI: Onsite Care Expansion Will Support Future Upside Potential
Analysts now set Cigna Group's fair value estimate at about $336.67, up from roughly $332.62, reflecting updated assumptions that incorporate slightly higher revenue growth, profit margins, and a lower future P/E multiple. What's in the News Cigna Group plans a leadership transition, with CEO David M.ナラティブ更新 • Feb 19
CI: Higher Margin Outlook And Onsite Care Expansion Will Support Upside
Analysts have modestly lifted their price target on Cigna Group to $332.62 from $326.92, citing updated assumptions that combine slightly lower revenue growth with a higher profit margin and a future P/E of 15.62. What's in the News A class action lawsuit has been filed against Express Scripts, Cigna, and Evernorth, alleging a rebate diversion scheme that used an offshore entity, Ascent, to collect billions of dollars in kickbacks labeled as fees instead of passing rebates through to pharmacy benefit management clients, including the Plumbers' Welfare Fund.ナラティブ更新 • Feb 04
CI: Onsite Clinic And Stable Assumptions Will Support Future Upside
Analysts have kept their price target for The Cigna Group broadly unchanged at about US$327, citing only slight adjustments to revenue growth, profit margin and future P/E assumptions rather than any major shift in their outlook. What's in the News Hankook Tire America Corp.ナラティブ更新 • Jan 21
CI: Completed Buybacks And New Employee Clinic Will Support Future Upside
Analysts have nudged their fair value estimate for Cigna Group slightly higher to US$326.92 from US$325.57, citing minor refinements to discount rate assumptions, revenue growth expectations, profit margin inputs, and the forward P/E multiple used in their models. What's in the News Hankook Tire America Corp.ナラティブ更新 • Jan 07
CI: Massive Share Buyback And Clinic Expansion Will Support Future Earnings Upside
Analysts have slightly reduced their price target for Cigna Group, trimming fair value by about $0.69 to $325.57 as they factor in a more moderate revenue growth outlook, along with a small improvement in expected profit margins and future P/E assumptions. What's in the News Hankook Tire America Corp.ナラティブ更新 • Dec 15
CI: Massive Share Buyback Will Drive Future Earnings Upside Momentum
Narrative Update on Cigna Group Analysts have slightly lowered their price target on Cigna Group by approximately $2 to around $326 per share, reflecting modest tweaks to assumptions on long term growth, profitability, and valuation multiples, while maintaining a broadly constructive outlook. What's in the News Cigna Group reported that between July 1 and September 30, 2025, it repurchased no additional shares under its existing authorization, having already completed the buyback of about 133.5 million shares, or 41.09% of shares outstanding, for roughly $34.44 billion since the program was announced in December 2018 (company filing).ナラティブ更新 • Nov 30
CI: Massive Share Buyback Will Drive Future Earnings Upside Momentum
Analysts have raised their price target for Cigna Group to $328.35 per share, citing moderate adjustments to key financial metrics. These include a higher projected future price-to-earnings ratio and continued expectations for growth and profitability.ナラティブ更新 • Nov 16
CI: Significant Buybacks And 2026 Guidance Will Drive Upside Momentum
Narrative Update on Cigna Group Analysts have lowered their price target for Cigna Group from $349.04 to $328.35. This change reflects adjustments for a slightly higher discount rate as well as revised expectations for revenue growth and profit margins.ナラティブ更新 • Nov 01
CI: Share Repurchase Momentum Will Drive Long-Term Shareholder Value Creation
Analysts have lowered their price target for Cigna Group from $369.13 to $349.04. This change reflects updated expectations around modestly higher revenue growth, which are offset by a slight dip in profit margin projections.Seeking Alpha • Mar 31
The Cigna Group: Compelling Exposure To Diversified Healthcare At A Discount Price
Summary Cigna is positioned to benefit from utilization normalization and aims for 10%-14% annual EPS growth by reducing Medicare exposure and improving Commercial business. Despite industry challenges, Cigna achieved 8%-9% YoY EPS growth in 2023-2024, demonstrating strong cost discipline and effective management. The sale of Cigna's Medicare unit and focus on lower-cost biosimilars and streamlined care accessibility are key strategic moves for future growth. With an attractive valuation and minimal downside risk, Cigna stock is rated a BUY, offering at least 33% upside potential even in bearish conditions. Read the full article on Seeking AlphaSeeking Alpha • Feb 17
Cigna Is A Buy: Market Overreaction Creates A Big Opportunity
Summary Cigna looks undervalued at under 10x earnings, with strong growth potential. Evernorth continues to expand, adding to the company’s long-term value. Large stock buybacks are supporting earnings per share and investor returns. Regulatory risks, rising costs, and competition remain challenges to watch. If Cigna meets its targets, the stock could rise 20-30% from here. Read the full article on Seeking AlphaSeeking Alpha • Jan 18
Cigna: Buy The Drop On This Undervalued Growth Stock
Summary Cigna's current valuation presents a compelling opportunity, trading at a forward PE of 9.9, significantly below its historical average of 12.0x. The company carries diversified revenue streams and consistent earnings growth, with Healthcare and Evernorth divisions driving strong performance and a 13% EPS CAGR over 10 years. Management targets 10-14% long-term annual EPS growth, supported by increased biosimilar adoption, behavioral health services growth, and aggressive share buybacks. CI's growing dividend and robust fundamentals make it an attractive choice for value and growth investors, despite potential regulatory and macroeconomic risks. Read the full article on Seeking AlphaSeeking Alpha • Dec 13
Cigna And The Risk Of PBMs - I'm Staying Out Above $230/Share
Summary Cigna faces significant risks due to potential healthcare reforms and scrutiny on PBMs, making it a "Hold" until it drops below $230/share. The US healthcare system's high costs and structural issues contribute to the uncertainty surrounding Cigna's long-term profitability and business model. Despite strong historical performance, the potential breakup of PBMs and legislative changes could drastically impact Cigna's future earnings and growth. The current valuation does not justify investment; Cigna's appeal lies in its fundamental strengths but is overshadowed by systemic risks and political uncertainties. Read the full article on Seeking Alpha株主還元
| CI | US Healthcare | US 市場 | |
|---|---|---|---|
| 7D | -4.1% | -0.3% | -2.0% |
| 1Y | -4.8% | 39.3% | 17.4% |
業界別リターン: CI過去 1 年間で39.3 % の収益を上げたUS Healthcare業界を下回りました。
リターン対市場: CIは、過去 1 年間で17.4 % のリターンを上げたUS市場を下回りました。
価格変動
| CI volatility | |
|---|---|
| CI Average Weekly Movement | 4.1% |
| Healthcare Industry Average Movement | 7.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: CI 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: CIの 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1792 | 66,685 | Brian Evanko | www.thecignagroup.com |
シグナ・グループはその子会社とともに、米国で保険および関連商品・サービスを提供している。つのセグメントを通して事業を行っている：Evernorth Health ServicesとCigna Healthcareである。エバーノース・ヘルスサービス部門は、薬局給付サービス部門と専門・介護サービス部門から成り、薬局給付管理、医薬品請求裁定、小売薬局ネットワーク管理、給付設計相談、医薬品利用審査、医薬品処方管理、薬局給付、在宅配達薬局、専門薬局、専門医薬品販売、全人的健康成果のための臨床プログラムなどを提供している。シグナ・ヘルスケア部門は、米国ヘルスケア部門と国際ヘルスケア部門で構成され、雇用者向け医療保険、個人・家族向け医療保険、行動医療保険、消費者向け医療保険、歯科医療保険、薬局管理保険、損害保険、グローバル・ヘルスケア、地域医療ソリューションなどの包括的な医療・協調ソリューション、および移動性の高い個人や多国籍組織の従業員向けの医療給付を提供している。その他、企業所有の生命保険、再保険、特定のランオフ事業や非戦略的事業も展開している。同社はブローカーやコンサルタント、雇用主、組合、その他の団体、個人への直接販売、民間および公的取引所を通じて商品とサービスを販売している。以前はシグナ・コーポレーションとして知られ、2023年2月にシグナ・グループに社名を変更した。同社は1792年に設立され、コネチカット州ブルームフィールドに本社を置いている。
The Cigna Group 基礎のまとめ
| CI 基礎統計学 | |
|---|---|
| 時価総額 | US$74.45b |
| 収益（TTM） | US$6.29b |
| 売上高(TTM) | US$277.89b |
11.8x
PER（株価収益率0.3x
P/SレシオCI は割高か？
公正価値と評価分析を参照収益と収入
| CI 損益計算書（TTM） | |
|---|---|
| 収益 | US$277.89b |
| 売上原価 | US$252.47b |
| 売上総利益 | US$25.42b |
| その他の費用 | US$19.14b |
| 収益 | US$6.29b |
直近の収益報告
Mar 31, 2026
次回決算日
Jul 30, 2026
| 一株当たり利益（EPS） | 23.77 |
| グロス・マージン | 9.15% |
| 純利益率 | 2.26% |
| 有利子負債／自己資本比率 | 72.8% |
CI の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
2.2%
現在の配当利回り26%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/19 01:26 |
| 終値 | 2026/07/17 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
The Cigna Group 17 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。37
| アナリスト | 機関 |
|---|---|
| null null | Argus Research Company |
| Hua Ha | Baird |
| Joshua Raskin | Barclays |